Testing effectiveness (Phase 2)Study completedNCT00000870
What this trial is testing
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 200